Little Green Pharma (LGP) identified supply chain issues and customer ordering cycles as reasons for a 19% decline in oil and flower sales in the third quarter of the 2024 financial year. Despite this, their new CherryCo product line has been successful, and they expect a positive impact from potential US cannabis reclassification.
Read the full story here
Written by: Steve Jones
Published on January 31, 2024 at 02:22PM
Source: Cannabiz (opens in new tab)